There are several controversies in the assessment of the benefit, value and sustainability of cancer drugs. First, there is a surprising disagreement on the impact of drugs on the overall outcome of cancer treatment. Second, raising the bar of efficacy in clinical trials is claimed by many, but at the same time, being conservative appears justified as well, given the overall benefit of multiple incremental gains, typically observed in advanced solid tumours. Third, sustainability of cancer drug cost is a prohibitive challenge, but no major successful action has been taken so far.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2uuJNIc
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Background. Reconstruction of surgical defects following cranial base surgery is challenging. Others have demonstrated that leukocyte-platel...
-
During lytic infection, herpes simplex virus (HSV) DNA is replicated by a mechanism involving DNA recombination. For instance, replication o...
-
Outcomes of multimodal management for sinonasal squamous cell carcinoma. J Craniomaxillofac Surg. 2017 May 12;: Authors: Paré A, Blan...
-
Abstract Purpose Low back pain is a significant problem for school-aged athletes. Although some risk factors relating to sports activiti...
-
Thyroid cancer is the most common malignant tumor of the endocrine system and the incidence has been increasing in recent years. In a great ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου